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Methicillin-resistant Staphylococcus aureus (MRSA) is a major
cause of human morbidity and mortality. MRSA emerged in the
early 1960s following the introduction of semi-synthetic,
b-lactamase stable penicillins such as methicillin [1]. During
the mid-1980s, epidemic strains spread to hospitals through-
out the world [2]. For nearly 30 years, MRSA was mainly
restricted to hospitals, probably because it had a selective
advantage compared with drug-susceptible wild-type S. aureus
strains.
In the 1990s MRSA was found in the community, in
particular in (healthy) individuals who had no direct or
indirect link with healthcare settings [3]. Since the beginning
of the twenty-ﬁrst century, community-associated MRSA has
been increasing at an alarming rate and has even reached
countries that have not had major problems with health-
care-associated MRSA infections, such as Denmark and the
Netherlands [4].
For a long time vancomycin has been considered as the
standard therapy for serious MRSA infections. However, since
1997 vancomycin use has been challenged by the emergence of
MRSA strains with decreased sensitivity to vancomycin [5].
This has prompted the search for novel antibiotics that are
efﬁcacious against MRSA.
Linezolid, an oxazolidinone class of antibiotic discovered in
the 1990s, was ﬁrst approved for use in 2000. In Europe,
linezolid is indicated to treat nosocomial pneumonia, when
known or suspected to be caused by susceptible Gram-posi-
tive bacteria; community-acquired pneumonia, when known or
suspected to be caused by susceptible Gram-positive bacteria;
and complicated skin and soft tissue infections, when micro-
biological testing has established that the infection is known to
be caused by susceptible Gram-positive bacteria.
Since its initial approval, there have been a multitude of
microbiological studies, clinical trials and research reports
evaluating the effectiveness of linezolid against serious MRSA
infections.
From the multiple anti-MRSA drugs that are alternatives to
vancomycin, such as clindamycin, trimethoprim-sulfamethox-
azole, cyclines, daptomycin, telavancin and ceftaroline [6], the
following reviews provide an up-to-date evaluation of the
clinical evidence for using linezolid to treat the two main
MRSA infections.
For complicated skin and soft tissue infections due to
MRSA, linezolid has demonstrated safety, clinical efﬁcacy and
favourable outcomes in treatment of these patients. Moreover,
with 100% oral bioavailability, the linezolid oral formulation
allowed a rapid transition from intravenous to oral therapy and
the possibility of an early discharge from the hospital.
Therefore, in eligible patients, linezolid reduced the length of
hospital stay and overall costs, making this treatment a viable
choice for the treatment of MRSA complicated skin and soft
tissue infections [7].
For nosocomial pneumonia due to MRSA, the take home
message is that vancomycin has remained a standard of care in
many European hospitals. However, there is evidence of
higher clinical efﬁcacy of linezolid in the treatment of MRSA
nosocomial pneumonia in a phase IV, randomized controlled
study compared with vancomycin, probably through greater
penetration into the epithelial lining ﬂuid of linezolid. More-
over, although overall healthcare resource use may be similar
between linezolid and vancomycin, linezolid leads to signiﬁ-
cantly lower incidence of renal failure than vancomycin, which
points to lower healthcare resource costs in linezolid-treated
patients [8].
In both indications, resistance to linezolid fortunately
remains rare. Most often it is due to a target-site mutation
in the 23S rRNA and is associated with prolonged use of
linezolid in chronic infections [9]. Recently, emergence of a
new mobile linezolid resistance determinant has been
reported, which could favour horizontal and interclonal
transmission of resistance; it should be closely monitored
[10].
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